nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—SLCO1B3—Methotrexate—lymphatic system cancer	0.224	0.34	CbGbCtD
Olmesartan—ABCC2—Vincristine—lymphatic system cancer	0.189	0.288	CbGbCtD
Olmesartan—SLCO1B1—Methotrexate—lymphatic system cancer	0.13	0.198	CbGbCtD
Olmesartan—ABCC2—Methotrexate—lymphatic system cancer	0.115	0.174	CbGbCtD
Olmesartan—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.000866	0.00253	CcSEcCtD
Olmesartan—Urticaria—Teniposide—lymphatic system cancer	0.000863	0.00252	CcSEcCtD
Olmesartan—Abdominal pain—Teniposide—lymphatic system cancer	0.000859	0.00251	CcSEcCtD
Olmesartan—Body temperature increased—Teniposide—lymphatic system cancer	0.000859	0.00251	CcSEcCtD
Olmesartan—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.000856	0.0025	CcSEcCtD
Olmesartan—Haematuria—Mitoxantrone—lymphatic system cancer	0.00085	0.00248	CcSEcCtD
Olmesartan—Oedema peripheral—Carmustine—lymphatic system cancer	0.000848	0.00248	CcSEcCtD
Olmesartan—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000846	0.00247	CcSEcCtD
Olmesartan—Dyspepsia—Fludarabine—lymphatic system cancer	0.000841	0.00246	CcSEcCtD
Olmesartan—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.000839	0.00245	CcSEcCtD
Olmesartan—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000836	0.00244	CcSEcCtD
Olmesartan—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000832	0.00243	CcSEcCtD
Olmesartan—Decreased appetite—Fludarabine—lymphatic system cancer	0.00083	0.00243	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000825	0.00241	CcSEcCtD
Olmesartan—Fatigue—Fludarabine—lymphatic system cancer	0.000824	0.00241	CcSEcCtD
Olmesartan—Pain—Fludarabine—lymphatic system cancer	0.000817	0.00239	CcSEcCtD
Olmesartan—Constipation—Fludarabine—lymphatic system cancer	0.000817	0.00239	CcSEcCtD
Olmesartan—Vasculitis—Methotrexate—lymphatic system cancer	0.000813	0.00238	CcSEcCtD
Olmesartan—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000811	0.00237	CcSEcCtD
Olmesartan—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.000808	0.00236	CcSEcCtD
Olmesartan—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000807	0.00236	CcSEcCtD
Olmesartan—Urethral disorder—Vincristine—lymphatic system cancer	0.000805	0.00235	CcSEcCtD
Olmesartan—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000802	0.00234	CcSEcCtD
Olmesartan—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000796	0.00233	CcSEcCtD
Olmesartan—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000794	0.00232	CcSEcCtD
Olmesartan—Anaemia—Bleomycin—lymphatic system cancer	0.000793	0.00232	CcSEcCtD
Olmesartan—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000787	0.0023	CcSEcCtD
Olmesartan—Asthenia—Teniposide—lymphatic system cancer	0.00078	0.00228	CcSEcCtD
Olmesartan—Malaise—Bleomycin—lymphatic system cancer	0.000774	0.00226	CcSEcCtD
Olmesartan—Pruritus—Teniposide—lymphatic system cancer	0.000769	0.00225	CcSEcCtD
Olmesartan—Arrhythmia—Carmustine—lymphatic system cancer	0.000769	0.00225	CcSEcCtD
Olmesartan—Leukopenia—Bleomycin—lymphatic system cancer	0.000768	0.00225	CcSEcCtD
Olmesartan—Alopecia—Carmustine—lymphatic system cancer	0.00076	0.00222	CcSEcCtD
Olmesartan—Body temperature increased—Fludarabine—lymphatic system cancer	0.000755	0.00221	CcSEcCtD
Olmesartan—Mental disorder—Carmustine—lymphatic system cancer	0.000754	0.0022	CcSEcCtD
Olmesartan—Malnutrition—Carmustine—lymphatic system cancer	0.000749	0.00219	CcSEcCtD
Olmesartan—Cough—Bleomycin—lymphatic system cancer	0.000749	0.00219	CcSEcCtD
Olmesartan—Angiopathy—Vincristine—lymphatic system cancer	0.000745	0.00218	CcSEcCtD
Olmesartan—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000745	0.00218	CcSEcCtD
Olmesartan—Diarrhoea—Teniposide—lymphatic system cancer	0.000744	0.00217	CcSEcCtD
Olmesartan—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00074	0.00216	CcSEcCtD
Olmesartan—Myalgia—Bleomycin—lymphatic system cancer	0.000731	0.00214	CcSEcCtD
Olmesartan—Chest pain—Bleomycin—lymphatic system cancer	0.000731	0.00214	CcSEcCtD
Olmesartan—Alopecia—Vincristine—lymphatic system cancer	0.000726	0.00212	CcSEcCtD
Olmesartan—Back pain—Carmustine—lymphatic system cancer	0.000725	0.00212	CcSEcCtD
Olmesartan—Discomfort—Bleomycin—lymphatic system cancer	0.000722	0.00211	CcSEcCtD
Olmesartan—Mental disorder—Vincristine—lymphatic system cancer	0.00072	0.0021	CcSEcCtD
Olmesartan—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000715	0.00209	CcSEcCtD
Olmesartan—Alopecia—Mitoxantrone—lymphatic system cancer	0.000707	0.00207	CcSEcCtD
Olmesartan—Vision blurred—Carmustine—lymphatic system cancer	0.000706	0.00206	CcSEcCtD
Olmesartan—Oedema—Bleomycin—lymphatic system cancer	0.0007	0.00205	CcSEcCtD
Olmesartan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0007	0.00205	CcSEcCtD
Olmesartan—Infection—Bleomycin—lymphatic system cancer	0.000696	0.00203	CcSEcCtD
Olmesartan—Anaemia—Carmustine—lymphatic system cancer	0.000692	0.00202	CcSEcCtD
Olmesartan—Back pain—Vincristine—lymphatic system cancer	0.000692	0.00202	CcSEcCtD
Olmesartan—Vomiting—Teniposide—lymphatic system cancer	0.000691	0.00202	CcSEcCtD
Olmesartan—Agitation—Carmustine—lymphatic system cancer	0.000688	0.00201	CcSEcCtD
Olmesartan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000686	0.002	CcSEcCtD
Olmesartan—Asthenia—Fludarabine—lymphatic system cancer	0.000685	0.002	CcSEcCtD
Olmesartan—Rash—Teniposide—lymphatic system cancer	0.000685	0.002	CcSEcCtD
Olmesartan—Dermatitis—Teniposide—lymphatic system cancer	0.000685	0.002	CcSEcCtD
Olmesartan—Headache—Teniposide—lymphatic system cancer	0.000681	0.00199	CcSEcCtD
Olmesartan—Pruritus—Fludarabine—lymphatic system cancer	0.000676	0.00198	CcSEcCtD
Olmesartan—Back pain—Mitoxantrone—lymphatic system cancer	0.000674	0.00197	CcSEcCtD
Olmesartan—Leukopenia—Carmustine—lymphatic system cancer	0.000671	0.00196	CcSEcCtD
Olmesartan—Anorexia—Bleomycin—lymphatic system cancer	0.000668	0.00195	CcSEcCtD
Olmesartan—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000662	0.00194	CcSEcCtD
Olmesartan—Anaemia—Vincristine—lymphatic system cancer	0.000661	0.00193	CcSEcCtD
Olmesartan—Agitation—Vincristine—lymphatic system cancer	0.000657	0.00192	CcSEcCtD
Olmesartan—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000656	0.00192	CcSEcCtD
Olmesartan—Hypotension—Bleomycin—lymphatic system cancer	0.000654	0.00191	CcSEcCtD
Olmesartan—Diarrhoea—Fludarabine—lymphatic system cancer	0.000654	0.00191	CcSEcCtD
Olmesartan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000646	0.00189	CcSEcCtD
Olmesartan—Nausea—Teniposide—lymphatic system cancer	0.000646	0.00189	CcSEcCtD
Olmesartan—Anaemia—Mitoxantrone—lymphatic system cancer	0.000644	0.00188	CcSEcCtD
Olmesartan—Vertigo—Vincristine—lymphatic system cancer	0.000642	0.00188	CcSEcCtD
Olmesartan—Leukopenia—Vincristine—lymphatic system cancer	0.00064	0.00187	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000638	0.00187	CcSEcCtD
Olmesartan—Chest pain—Carmustine—lymphatic system cancer	0.000638	0.00186	CcSEcCtD
Olmesartan—Myalgia—Carmustine—lymphatic system cancer	0.000638	0.00186	CcSEcCtD
Olmesartan—Anxiety—Carmustine—lymphatic system cancer	0.000636	0.00186	CcSEcCtD
Olmesartan—Malaise—Mitoxantrone—lymphatic system cancer	0.000628	0.00184	CcSEcCtD
Olmesartan—Renal failure acute—Methotrexate—lymphatic system cancer	0.000624	0.00182	CcSEcCtD
Olmesartan—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000623	0.00182	CcSEcCtD
Olmesartan—Oedema—Carmustine—lymphatic system cancer	0.000611	0.00179	CcSEcCtD
Olmesartan—Decreased appetite—Bleomycin—lymphatic system cancer	0.000609	0.00178	CcSEcCtD
Olmesartan—Myalgia—Vincristine—lymphatic system cancer	0.000609	0.00178	CcSEcCtD
Olmesartan—Cough—Mitoxantrone—lymphatic system cancer	0.000608	0.00178	CcSEcCtD
Olmesartan—Infection—Carmustine—lymphatic system cancer	0.000607	0.00178	CcSEcCtD
Olmesartan—Vomiting—Fludarabine—lymphatic system cancer	0.000607	0.00178	CcSEcCtD
Olmesartan—Rash—Fludarabine—lymphatic system cancer	0.000602	0.00176	CcSEcCtD
Olmesartan—Dermatitis—Fludarabine—lymphatic system cancer	0.000602	0.00176	CcSEcCtD
Olmesartan—Pain—Bleomycin—lymphatic system cancer	0.000599	0.00175	CcSEcCtD
Olmesartan—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000599	0.00175	CcSEcCtD
Olmesartan—Headache—Fludarabine—lymphatic system cancer	0.000598	0.00175	CcSEcCtD
Olmesartan—Tachycardia—Carmustine—lymphatic system cancer	0.000597	0.00174	CcSEcCtD
Olmesartan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000593	0.00173	CcSEcCtD
Olmesartan—Chest pain—Mitoxantrone—lymphatic system cancer	0.000593	0.00173	CcSEcCtD
Olmesartan—Myalgia—Mitoxantrone—lymphatic system cancer	0.000593	0.00173	CcSEcCtD
Olmesartan—Anxiety—Mitoxantrone—lymphatic system cancer	0.000591	0.00173	CcSEcCtD
Olmesartan—Lethargy—Methotrexate—lymphatic system cancer	0.000588	0.00172	CcSEcCtD
Olmesartan—Discomfort—Mitoxantrone—lymphatic system cancer	0.000586	0.00171	CcSEcCtD
Olmesartan—Oedema—Vincristine—lymphatic system cancer	0.000584	0.00171	CcSEcCtD
Olmesartan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000584	0.00171	CcSEcCtD
Olmesartan—Anorexia—Carmustine—lymphatic system cancer	0.000583	0.0017	CcSEcCtD
Olmesartan—Infection—Vincristine—lymphatic system cancer	0.00058	0.0017	CcSEcCtD
Olmesartan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000577	0.00169	CcSEcCtD
Olmesartan—Nervous system disorder—Vincristine—lymphatic system cancer	0.000572	0.00167	CcSEcCtD
Olmesartan—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000571	0.00167	CcSEcCtD
Olmesartan—Hypotension—Carmustine—lymphatic system cancer	0.000571	0.00167	CcSEcCtD
Olmesartan—Oedema—Mitoxantrone—lymphatic system cancer	0.000568	0.00166	CcSEcCtD
Olmesartan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000568	0.00166	CcSEcCtD
Olmesartan—Nausea—Fludarabine—lymphatic system cancer	0.000567	0.00166	CcSEcCtD
Olmesartan—Infection—Mitoxantrone—lymphatic system cancer	0.000565	0.00165	CcSEcCtD
Olmesartan—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000564	0.00165	CcSEcCtD
Olmesartan—Shock—Mitoxantrone—lymphatic system cancer	0.000559	0.00163	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000557	0.00163	CcSEcCtD
Olmesartan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000557	0.00163	CcSEcCtD
Olmesartan—Urticaria—Bleomycin—lymphatic system cancer	0.000556	0.00163	CcSEcCtD
Olmesartan—Anorexia—Vincristine—lymphatic system cancer	0.000556	0.00163	CcSEcCtD
Olmesartan—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000555	0.00162	CcSEcCtD
Olmesartan—Body temperature increased—Bleomycin—lymphatic system cancer	0.000554	0.00162	CcSEcCtD
Olmesartan—Insomnia—Carmustine—lymphatic system cancer	0.000553	0.00162	CcSEcCtD
Olmesartan—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000552	0.00161	CcSEcCtD
Olmesartan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000549	0.00161	CcSEcCtD
Olmesartan—Hypotension—Vincristine—lymphatic system cancer	0.000545	0.00159	CcSEcCtD
Olmesartan—Anorexia—Mitoxantrone—lymphatic system cancer	0.000542	0.00158	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000532	0.00155	CcSEcCtD
Olmesartan—Decreased appetite—Carmustine—lymphatic system cancer	0.000531	0.00155	CcSEcCtD
Olmesartan—Hypotension—Mitoxantrone—lymphatic system cancer	0.000531	0.00155	CcSEcCtD
Olmesartan—Insomnia—Vincristine—lymphatic system cancer	0.000528	0.00154	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000528	0.00154	CcSEcCtD
Olmesartan—Pain—Carmustine—lymphatic system cancer	0.000523	0.00153	CcSEcCtD
Olmesartan—Constipation—Carmustine—lymphatic system cancer	0.000523	0.00153	CcSEcCtD
Olmesartan—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000519	0.00152	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000518	0.00151	CcSEcCtD
Olmesartan—Decreased appetite—Vincristine—lymphatic system cancer	0.000507	0.00148	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000504	0.00147	CcSEcCtD
Olmesartan—Feeling abnormal—Carmustine—lymphatic system cancer	0.000504	0.00147	CcSEcCtD
Olmesartan—Fatigue—Vincristine—lymphatic system cancer	0.000503	0.00147	CcSEcCtD
Olmesartan—Asthenia—Bleomycin—lymphatic system cancer	0.000503	0.00147	CcSEcCtD
Olmesartan—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0005	0.00146	CcSEcCtD
Olmesartan—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.0005	0.00146	CcSEcCtD
Olmesartan—Pain—Vincristine—lymphatic system cancer	0.000499	0.00146	CcSEcCtD
Olmesartan—Constipation—Vincristine—lymphatic system cancer	0.000499	0.00146	CcSEcCtD
Olmesartan—Pruritus—Bleomycin—lymphatic system cancer	0.000496	0.00145	CcSEcCtD
Olmesartan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000494	0.00144	CcSEcCtD
Olmesartan—Eosinophilia—Methotrexate—lymphatic system cancer	0.000493	0.00144	CcSEcCtD
Olmesartan—Fatigue—Mitoxantrone—lymphatic system cancer	0.00049	0.00143	CcSEcCtD
Olmesartan—Pancreatitis—Methotrexate—lymphatic system cancer	0.000488	0.00143	CcSEcCtD
Olmesartan—Pain—Mitoxantrone—lymphatic system cancer	0.000486	0.00142	CcSEcCtD
Olmesartan—Constipation—Mitoxantrone—lymphatic system cancer	0.000486	0.00142	CcSEcCtD
Olmesartan—Body temperature increased—Carmustine—lymphatic system cancer	0.000483	0.00141	CcSEcCtD
Olmesartan—Abdominal pain—Carmustine—lymphatic system cancer	0.000483	0.00141	CcSEcCtD
Olmesartan—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000477	0.0014	CcSEcCtD
Olmesartan—Pancytopenia—Methotrexate—lymphatic system cancer	0.000473	0.00138	CcSEcCtD
Olmesartan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000468	0.00137	CcSEcCtD
Olmesartan—Neutropenia—Methotrexate—lymphatic system cancer	0.000466	0.00136	CcSEcCtD
Olmesartan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000465	0.00136	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000463	0.00135	CcSEcCtD
Olmesartan—Body temperature increased—Vincristine—lymphatic system cancer	0.000461	0.00135	CcSEcCtD
Olmesartan—Abdominal pain—Vincristine—lymphatic system cancer	0.000461	0.00135	CcSEcCtD
Olmesartan—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000459	0.00134	CcSEcCtD
Olmesartan—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000455	0.00133	CcSEcCtD
Olmesartan—Urticaria—Mitoxantrone—lymphatic system cancer	0.000452	0.00132	CcSEcCtD
Olmesartan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000449	0.00131	CcSEcCtD
Olmesartan—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000449	0.00131	CcSEcCtD
Olmesartan—Pneumonia—Methotrexate—lymphatic system cancer	0.000447	0.00131	CcSEcCtD
Olmesartan—Vomiting—Bleomycin—lymphatic system cancer	0.000445	0.0013	CcSEcCtD
Olmesartan—Infestation NOS—Methotrexate—lymphatic system cancer	0.000444	0.0013	CcSEcCtD
Olmesartan—Infestation—Methotrexate—lymphatic system cancer	0.000444	0.0013	CcSEcCtD
Olmesartan—Rash—Bleomycin—lymphatic system cancer	0.000442	0.00129	CcSEcCtD
Olmesartan—Dermatitis—Bleomycin—lymphatic system cancer	0.000441	0.00129	CcSEcCtD
Olmesartan—Asthenia—Carmustine—lymphatic system cancer	0.000439	0.00128	CcSEcCtD
Olmesartan—Renal failure—Methotrexate—lymphatic system cancer	0.000436	0.00128	CcSEcCtD
Olmesartan—Haematuria—Methotrexate—lymphatic system cancer	0.000423	0.00124	CcSEcCtD
Olmesartan—Asthenia—Vincristine—lymphatic system cancer	0.000419	0.00122	CcSEcCtD
Olmesartan—Diarrhoea—Carmustine—lymphatic system cancer	0.000418	0.00122	CcSEcCtD
Olmesartan—Nausea—Bleomycin—lymphatic system cancer	0.000416	0.00122	CcSEcCtD
Olmesartan—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000414	0.00121	CcSEcCtD
Olmesartan—Asthenia—Mitoxantrone—lymphatic system cancer	0.000408	0.00119	CcSEcCtD
Olmesartan—Dizziness—Carmustine—lymphatic system cancer	0.000404	0.00118	CcSEcCtD
Olmesartan—Diarrhoea—Vincristine—lymphatic system cancer	0.000399	0.00117	CcSEcCtD
Olmesartan—Pharyngitis—Methotrexate—lymphatic system cancer	0.000396	0.00116	CcSEcCtD
Olmesartan—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000394	0.00115	CcSEcCtD
Olmesartan—Urethral disorder—Methotrexate—lymphatic system cancer	0.000391	0.00114	CcSEcCtD
Olmesartan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000389	0.00114	CcSEcCtD
Olmesartan—Vomiting—Carmustine—lymphatic system cancer	0.000389	0.00114	CcSEcCtD
Olmesartan—Dizziness—Vincristine—lymphatic system cancer	0.000386	0.00113	CcSEcCtD
Olmesartan—Rash—Carmustine—lymphatic system cancer	0.000385	0.00113	CcSEcCtD
Olmesartan—Dermatitis—Carmustine—lymphatic system cancer	0.000385	0.00113	CcSEcCtD
Olmesartan—Headache—Carmustine—lymphatic system cancer	0.000383	0.00112	CcSEcCtD
Olmesartan—Vomiting—Vincristine—lymphatic system cancer	0.000371	0.00108	CcSEcCtD
Olmesartan—Rash—Vincristine—lymphatic system cancer	0.000368	0.00108	CcSEcCtD
Olmesartan—Dermatitis—Vincristine—lymphatic system cancer	0.000368	0.00107	CcSEcCtD
Olmesartan—Headache—Vincristine—lymphatic system cancer	0.000366	0.00107	CcSEcCtD
Olmesartan—Nausea—Carmustine—lymphatic system cancer	0.000363	0.00106	CcSEcCtD
Olmesartan—Angiopathy—Methotrexate—lymphatic system cancer	0.000362	0.00106	CcSEcCtD
Olmesartan—Vomiting—Mitoxantrone—lymphatic system cancer	0.000361	0.00106	CcSEcCtD
Olmesartan—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000359	0.00105	CcSEcCtD
Olmesartan—Rash—Mitoxantrone—lymphatic system cancer	0.000358	0.00105	CcSEcCtD
Olmesartan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000358	0.00105	CcSEcCtD
Olmesartan—Headache—Mitoxantrone—lymphatic system cancer	0.000356	0.00104	CcSEcCtD
Olmesartan—Alopecia—Methotrexate—lymphatic system cancer	0.000352	0.00103	CcSEcCtD
Olmesartan—Mental disorder—Methotrexate—lymphatic system cancer	0.000349	0.00102	CcSEcCtD
Olmesartan—Malnutrition—Methotrexate—lymphatic system cancer	0.000347	0.00101	CcSEcCtD
Olmesartan—Nausea—Vincristine—lymphatic system cancer	0.000347	0.00101	CcSEcCtD
Olmesartan—Nausea—Mitoxantrone—lymphatic system cancer	0.000338	0.000987	CcSEcCtD
Olmesartan—Back pain—Methotrexate—lymphatic system cancer	0.000336	0.000981	CcSEcCtD
Olmesartan—Vision blurred—Methotrexate—lymphatic system cancer	0.000327	0.000956	CcSEcCtD
Olmesartan—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000322	0.000941	CcSEcCtD
Olmesartan—Anaemia—Methotrexate—lymphatic system cancer	0.000321	0.000938	CcSEcCtD
Olmesartan—Malaise—Methotrexate—lymphatic system cancer	0.000313	0.000915	CcSEcCtD
Olmesartan—Vertigo—Methotrexate—lymphatic system cancer	0.000312	0.000911	CcSEcCtD
Olmesartan—Leukopenia—Methotrexate—lymphatic system cancer	0.000311	0.000908	CcSEcCtD
Olmesartan—Cough—Methotrexate—lymphatic system cancer	0.000303	0.000885	CcSEcCtD
Olmesartan—Arthralgia—Methotrexate—lymphatic system cancer	0.000295	0.000864	CcSEcCtD
Olmesartan—Myalgia—Methotrexate—lymphatic system cancer	0.000295	0.000864	CcSEcCtD
Olmesartan—Chest pain—Methotrexate—lymphatic system cancer	0.000295	0.000864	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000293	0.000858	CcSEcCtD
Olmesartan—Discomfort—Methotrexate—lymphatic system cancer	0.000292	0.000853	CcSEcCtD
Olmesartan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000283	0.000828	CcSEcCtD
Olmesartan—Infection—Methotrexate—lymphatic system cancer	0.000281	0.000822	CcSEcCtD
Olmesartan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000278	0.000812	CcSEcCtD
Olmesartan—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000277	0.000811	CcSEcCtD
Olmesartan—Skin disorder—Methotrexate—lymphatic system cancer	0.000275	0.000804	CcSEcCtD
Olmesartan—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000274	0.0008	CcSEcCtD
Olmesartan—Anorexia—Methotrexate—lymphatic system cancer	0.00027	0.000789	CcSEcCtD
Olmesartan—Hypotension—Methotrexate—lymphatic system cancer	0.000265	0.000774	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000258	0.000754	CcSEcCtD
Olmesartan—Insomnia—Methotrexate—lymphatic system cancer	0.000256	0.000749	CcSEcCtD
Olmesartan—Dyspepsia—Methotrexate—lymphatic system cancer	0.000249	0.000729	CcSEcCtD
Olmesartan—Decreased appetite—Methotrexate—lymphatic system cancer	0.000246	0.00072	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000244	0.000715	CcSEcCtD
Olmesartan—Fatigue—Methotrexate—lymphatic system cancer	0.000244	0.000714	CcSEcCtD
Olmesartan—Pain—Methotrexate—lymphatic system cancer	0.000242	0.000708	CcSEcCtD
Olmesartan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000233	0.000682	CcSEcCtD
Olmesartan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000232	0.000677	CcSEcCtD
Olmesartan—Urticaria—Methotrexate—lymphatic system cancer	0.000225	0.000658	CcSEcCtD
Olmesartan—Abdominal pain—Methotrexate—lymphatic system cancer	0.000224	0.000654	CcSEcCtD
Olmesartan—Body temperature increased—Methotrexate—lymphatic system cancer	0.000224	0.000654	CcSEcCtD
Olmesartan—Asthenia—Methotrexate—lymphatic system cancer	0.000203	0.000594	CcSEcCtD
Olmesartan—Pruritus—Methotrexate—lymphatic system cancer	0.0002	0.000586	CcSEcCtD
Olmesartan—Diarrhoea—Methotrexate—lymphatic system cancer	0.000194	0.000566	CcSEcCtD
Olmesartan—Dizziness—Methotrexate—lymphatic system cancer	0.000187	0.000547	CcSEcCtD
Olmesartan—Vomiting—Methotrexate—lymphatic system cancer	0.00018	0.000526	CcSEcCtD
Olmesartan—Rash—Methotrexate—lymphatic system cancer	0.000179	0.000522	CcSEcCtD
Olmesartan—Dermatitis—Methotrexate—lymphatic system cancer	0.000178	0.000522	CcSEcCtD
Olmesartan—Headache—Methotrexate—lymphatic system cancer	0.000177	0.000519	CcSEcCtD
Olmesartan—Nausea—Methotrexate—lymphatic system cancer	0.000168	0.000492	CcSEcCtD
